Paradigm is a Next Generation Sequencing (NGS) assay that enables the detection of clinically

relevant genomic alterations (SNVs, CNVs, Indels and Gene fusions) from circulating tumor DNA (ctDNA),

within 531 clinically relevant genes . The assay additionally provides the tumor mutation burden (TMB) score

and Microsatellite Instability (MSI) score and status for optimum therapy selection, prognostication and aids in

drug discovery research and clinical trial research programs